Immunovant Inc.
Cash Flow Statement
| Line Item | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-40.4M | $-47.2M | $-41.4M | $-37.7M | $-30.5M | $-28.2M | $-31.8M | $-20.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $44.0K | $39.0K | $33.0K | $28.0K | $26.0K | $22.0K | $19.0K | $14.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.7M | $11.9M | $10.2M | $8.4M | $3.9M | $5.5M | $6.0M | $3.4M |
| Net Cash from Operating Activities | $-65.8M | $-33.0M | $-31.9M | $-20.0M | $-21.2M | $-22.5M | $-22.8M | $-24.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $42.0K | $118.0K | $74.0K | $44.0K | $18.0K | $95.0K | $29.0K | $39.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-42.0K | $-118.0K | $-74.0K | $-44.0K | $-18.0K | $-95.0K | $-29.0K | $-39.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $21.0K | $0 | $0 | $200.0M | $91.0K | $763.0K | $446.0K | $188.4M |
| Net Change in Cash | $-66.6M | $-33.2M | $-31.9M | $179.9M | $-21.1M | $-21.8M | $-22.4M | $164.1M |
| Free Cash Flow | $-65.9M | $-33.1M | $-32.0M | $-20.1M | $-21.2M | $-22.6M | $-22.8M | $-24.3M |